New CMS Mandate on Diabetes Harm Measures: What You Need to Know

Dr Paul Chidester, MD | Chief Medical Officer

The Centers for Medicare & Medicaid Services (CMS) recently announced a pivotal update on April 10, 2024, that mandates the reporting of severe hypoglycemia and hyperglycemia incidents.

This new rule, effective for the CY 2026 reporting period, marks a significant shift from previous guidelines and has profound implications for healthcare providers and technology partners like Monarch Medical Technologies.

Here’s what you need to know.

From Voluntary to Mandatory: The Evolution of Glycemic Event Reporting

Historically, CMS’s 2022 announcement allowed hospitals the flexibility to voluntarily report glycemic events. This initial step was crucial in building a transparent, quality-focused healthcare system but did not mandate participation.

Fast forward to 2024, and the landscape has drastically changed. Under the new rule, all hospitals are required to report these metrics as part of the Inpatient Quality Reporting (IQR) program.

Non-compliance will lead to significant financial repercussions, including a reduction in annual payments under the Inpatient Prospective Payment System (IPPS).

What Does This Mean for Hospitals?

The latest CMS mandate underscores the increasing importance of accurate, real-time glycemic management in hospitals. As healthcare systems now face financial penalties for non-compliance, the demand for reliable computer-based decision support tools is expected to surge.

Monarch Medical Technologies is positioned to meet this demand with its market leading glycemic management solution EndoTool, that not only ensures compliance but also enhances patient care and healthcare workers workflows through optimized glycemic management.

Is Now the Time for Clinical Decision Support Software?

The new CMS mandate is a game-changer for Clinical Decision Support Software (CDSS). With financial penalties at stake, hospitals are now more than ever focused on tangible returns on investment.

Furthermore, the Society of Critical Care Medicine (SCCM), during their presentation at the 2024 Critical Care Congress, highlighted the updated glycemic control guidelines that emphasize a strategic approach to managing critically ill patients. These guidelines stress the importance of individualized patient care, the minimization of hypoglycemia, and the integration of advanced technologies like CDSS tools, aligning with the SCCM’s support for these systems in clinical practice.

CDSS for glycemic management offers significant benefits, such as improved ICU bed utilization and shorter lengths of stay—metrics that are now crucial for hospitals aiming to avoid penalties and maximize reimbursements.

Why EndoTool Glycemic Management System?

  • Enhanced Compliance: With EndoTool, our user-friendly glycemic management solution, your hospital will not only comply with new mandates but excel in them.
  • Proven ROI: Improve your ICU bed utilization and reduce the length of stays, converting improved patient outcomes into tangible financial benefits.
  • Priority Support: We ensure seamless integration and ongoing support, making the transition as painless as possible for your staff.

Where to From Here?

The recent CMS rule change is a call to action for healthcare providers. As hospitals adapt to these new requirements, Monarch Medical Technologies is ready to lead the way with solutions that not only comply with regulatory demands but also drive substantial improvements in patient outcomes and hospital efficiency.

For more information on how our technologies can help your institution navigate these changes, request a demonstration today.

About the Author(s)
Dr Paul Chidester, MD | Chief Medical Officer

Dr. Paul Chidester is the Chief Medical Officer for Monarch Medical Technologies. After practicing for two decades as a nephrologist, he assumed a senior leadership role at Sentara Healthcare where he led the implementation of computerized insulin dosing software. He is involved with product development and customer engagement at Monarch Medical Technologies where the focus is to provide precision insulin dosing for patients. His key interest is working to further enhance this precision through the use of technologies such as CGM.